The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 13, 2022

Filed:

Jan. 04, 2019
Applicant:

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Mark Lackner, South San Francisco, CA (US);

Daniel Maslyar, San Carlos, CA (US);

Yulei Wang, South San Francisco, CA (US);

Walter Darbonne, San Mateo, CA (US);

Eric Humke, Redwood City, CA (US);

Assignee:

Genentech, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 47/68 (2017.01); G01N 33/574 (2006.01); A61K 47/65 (2017.01); A61P 35/00 (2006.01); A61K 31/22 (2006.01); A61K 31/7048 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3092 (2013.01); A61K 31/22 (2013.01); A61K 31/7048 (2013.01); A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/6817 (2017.08); A61K 47/6859 (2017.08); A61K 47/6869 (2017.08); A61P 35/00 (2018.01); C07K 16/2896 (2013.01); G01N 33/57407 (2013.01); G01N 33/57449 (2013.01); G01N 33/57484 (2013.01); A61K 2039/505 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.


Find Patent Forward Citations

Loading…